In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report), with a price target of $53.00. The company's shares closed yesterday at $12.51.Pantginis covers the Healthcare sector, focusing on stocks such as Palatin Technologies, Actinium Pharmaceuticals, and PDS Biotechnology. According to TipRanks, Pantginis has an average return of -16.9% and a 30.95% success rate on recommended stocks. Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $30.00, implying a 139.81% upside from current levels.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-gets-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals